Immunocore Holdings Stock Z Score
| IMCR Stock | USD 55.82 0.14 0.25% |
Immunocore | Z Score |
Immunocore Holdings Company Z Score Analysis
Immunocore Holdings' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Immunocore Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Immunocore Holdings is extremely important. It helps to project a fair market value of Immunocore Stock properly, considering its historical fundamentals such as Z Score. Since Immunocore Holdings' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunocore Holdings' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunocore Holdings' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
According to the company's disclosures, Immunocore Holdings has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Immunocore Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunocore Holdings' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunocore Holdings could also be used in its relative valuation, which is a method of valuing Immunocore Holdings by comparing valuation metrics of similar companies.Immunocore Holdings is currently under evaluation in z score category among related companies.
Immunocore Holdings Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immunocore Holdings from analyzing Immunocore Holdings' financial statements. These drivers represent accounts that assess Immunocore Holdings' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunocore Holdings' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 889.4B | 1.0B | 1.1B | 2.2B | 3.3T | 3.5T | |
| Enterprise Value | 889.4B | 938.8M | 903.7M | 1.9B | 3.3T | 3.5T |
Immunocore Holdings Institutional Holders
Institutional Holdings refers to the ownership stake in Immunocore Holdings that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Immunocore Holdings' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunocore Holdings' value.| Shares | Fiera Capital Corporation | 2023-12-31 | 846.8 K | Pictet Asset Manangement Sa | 2023-12-31 | 809.6 K | Blackrock Inc | 2023-12-31 | 779 K | Bill & Melinda Gates Foundation | 2023-12-31 | 576.9 K | Cowen And Company, Llc | 2023-12-31 | 536.5 K | Polar Capital Holdings Plc | 2023-12-31 | 501.3 K | Principal Financial Group Inc | 2023-12-31 | 483.3 K | Tang Capital Management Llc | 2023-09-30 | 405.6 K | Logos Global Management Lp | 2023-12-31 | 400 K | Rtw Investments, Llc | 2023-12-31 | 6.1 M | Wellington Management Company Llp | 2023-12-31 | 4.3 M |
Immunocore Fundamentals
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.0674 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 2.42 B | ||||
| Shares Outstanding | 48.76 M | ||||
| Shares Owned By Insiders | 4.55 % | ||||
| Shares Owned By Institutions | 84.13 % | ||||
| Number Of Shares Shorted | 4.61 M | ||||
| Price To Book | 6.09 X | ||||
| Price To Sales | 11.29 X | ||||
| Revenue | 249.43 M | ||||
| Gross Profit | 54.11 M | ||||
| EBITDA | (38.47 M) | ||||
| Net Income | (55.29 M) | ||||
| Cash And Equivalents | 208.06 M | ||||
| Cash Per Share | 4.74 X | ||||
| Total Debt | 84.03 M | ||||
| Debt To Equity | 0.41 % | ||||
| Current Ratio | 3.98 X | ||||
| Book Value Per Share | 7.42 X | ||||
| Cash Flow From Operations | 2.94 M | ||||
| Short Ratio | 10.75 X | ||||
| Earnings Per Share | (1.40) X | ||||
| Target Price | 85.4 | ||||
| Number Of Employees | 497 | ||||
| Beta | 0.89 | ||||
| Market Capitalization | 2.71 B | ||||
| Total Asset | 597 M | ||||
| Retained Earnings | (744.67 M) | ||||
| Working Capital | 389.8 M | ||||
| Net Asset | 597 M |
About Immunocore Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunocore Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunocore Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunocore Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Immunocore Holdings Piotroski F Score and Immunocore Holdings Valuation analysis. To learn how to invest in Immunocore Stock, please use our How to Invest in Immunocore Holdings guide.Note that the Immunocore Holdings information on this page should be used as a complementary analysis to other Immunocore Holdings' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Immunocore Stock analysis
When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Immunocore Holdings' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunocore Holdings. If investors know Immunocore will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunocore Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.68) | Earnings Share (1.40) | Revenue Per Share 5.102 | Quarterly Revenue Growth 0.122 | Return On Assets (0.07) |
The market value of Immunocore Holdings is measured differently than its book value, which is the value of Immunocore that is recorded on the company's balance sheet. Investors also form their own opinion of Immunocore Holdings' value that differs from its market value or its book value, called intrinsic value, which is Immunocore Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunocore Holdings' market value can be influenced by many factors that don't directly affect Immunocore Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunocore Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunocore Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunocore Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.